Overview

Effect of GLP-1 on Postprandial Lipid Metabolism

Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Individuals with obesity have an increased risk for heart disease and diabetes. There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes. The investigators want to determine if targeting this hormone will also help people with high cholesterol and triglycerides. In this study, the investigators are looking at the role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.
Phase:
N/A
Details
Lead Sponsor:
David Dalessio
Treatments:
Glucagon
Glucagon-Like Peptide 1